ABSTRACT
Introduction There is ample evidence of a high prevalence of dyslipidaemia and of increased risk of cardiovascular disease (CVD) in patients with renal impairment |l|. Even mild renal insufficiency significantly increased the risk of cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study |2|. Treatment with hypolipidaemic drugs to reduce the risk of cardiovascular events in renal disease is, however, to some extent an act of faith based on extrapolation from trials in subjects with normal renal function.
